Consequently, different gene expression signatures related to the tumor microenvironment have been described as predictive markers of clinical benefit in patients undergoing anti PD-1/PD-L1 treatment [171,184,185,186,187,188,189]. The gene discussed is CD274; the disease is neoplasm.